Literature DB >> 9737237

Neuroendocrine differentiation is a common feature of thymic carcinoma.

L Lauriola1, R A Erlandson, J Rosai.   

Abstract

Immunohistochemical evidence of neuroendocrine differentiation in the form of reactivity for synaptophysin, neuron-specific enolase, and/or chromogranin was found in 11 of 19 (58%) thymic carcinomas having the typical morphologic features of that tumor type. Four of these 19 cases were studied ultrastructurally, and neuroendocrine-type cytoplasmic dense-core granules were found in two. In contrast, 84 thymomas were negative for these markers, except for a focal immunoreactivity for neuron-specific enolase in areas of medullary differentiation in half of the lymphocyte-rich tumors. The results of this study show that in the thymus, similar to most other organs, neuroendocrine differentiation is not limited to tumors with an identifiable neuroendocrine appearance in hematoxylin-eosin-stained slides, such as carcinoid tumor and small cell carcinoma, but rather that it represents a common event shared by the major types of malignant epithelial tumors of that organ.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737237     DOI: 10.1097/00000478-199809000-00003

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  15 in total

Review 1.  Neuroendocrine tumors of the thymus and mediastinum.

Authors:  Hanibal Bohnenberger; Helen Dinter; Alexander König; Philipp Ströbel
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

2.  Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors.

Authors:  Priska Leisibach; Didier Schneiter; Alex Soltermann; Yoshi Yamada; Walter Weder; Wolfgang Jungraithmayr
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 3.  Thymoma and thymic carcinoma: an update of the WHO Classification 2004.

Authors:  Philipp Ströbel; Alexander Marx; Andreas Zettl; Hans Konrad Müller-Hermelink
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

Review 4.  [Thymic carcinomas].

Authors:  P Ströbel; C-A Weis; A Marx
Journal:  Pathologe       Date:  2016-09       Impact factor: 1.011

5.  Atypical thymoma (WHO B3) with neuroendocrine differentiation: report of a case.

Authors:  Junichi Shiraishi; Hiroaki Nomori; Hideki Orikasa; Taisuke Mori; Kazuto Yamazaki
Journal:  Virchows Arch       Date:  2006-05-04       Impact factor: 4.064

6.  Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift.

Authors:  Alessandra Fabbri; Mara Cossa; Angelica Sonzogni; Paolo Bidoli; Stefania Canova; Diego Cortinovis; Maria Ida Abbate; Fiorella Calabrese; Nazarena Nannini; Francesca Lunardi; Giulio Rossi; Stefano La Rosa; Carlo Capella; Elena Tamborini; Federica Perrone; Adele Busico; Iolanda Capone; Barbara Valeri; Ugo Pastorino; Adriana Albini; Giuseppe Pelosi
Journal:  Virchows Arch       Date:  2017-04-27       Impact factor: 4.064

Review 7.  [Neuroendocrine neoplasms of the mediastinum].

Authors:  L Brcic; M Heidinger; H Popper
Journal:  Pathologe       Date:  2016-09       Impact factor: 1.011

8.  Thymoma with ganglioneuroblastomatous component: case report.

Authors:  Kenji Kashiwabara; Hayato Ikota; Shigebumi Tanaka; Chie Ohta; Toshiki Yajima; Hideki Endoh; Ei Yamaki; Hiroyuki Kuwano; Takashi Nakajima
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

Review 9.  Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms.

Authors:  Marco Volante; Luisella Righi; Sofia Asioli; Gianni Bussolati; Mauro Papotti
Journal:  Virchows Arch       Date:  2007-08-08       Impact factor: 4.064

10.  Thymomas: a cytological and immunohistochemical study, with emphasis on lymphoid and neuroendocrine markers.

Authors:  Borislav A Alexiev; Cinthia B Drachenberg; Allen P Burke
Journal:  Diagn Pathol       Date:  2007-05-11       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.